@Article{Zheng2025,
journal="Folia Neuropathologica",
issn="1641-4640",
volume="63",
number="4",
year="2025",
title="NAD+ attenuates central nervous system demyelination in experimental autoimmune encephalomyelitis mice",
abstract="Nicotinamide adenine dinucleotide (NAD + ) supplementation attenuates demyelination in the experimental autoimmune encephalomyelitis (EAE) model. The aim of the study was to confirm the therapeutic effect of NAD +  on the EAE model and investigate its protective mechanism. Mice were divided into 3 groups: EAE, EAE + NAD + , and Control (Ctrl). EAE and EAE + NAD +  groups were induced with myelin oligodendrocyte glycoprotein (MOG) to initiate the demyelination process. The EAE + NAD +  group received an NAD +  injection at a dosage of 250 mg/kg/day. Clinical, neuroinflammation, and neurodemyelination scores were monitored. At the peak of onset, animals were euthanized, and mRNA expression level in the spinal cord was tested. NAD +  supplementation promoted the conversion of regulatory T cells (Tregs) into T helper 17 (Th17) cells with increased concentrations of NAD + . NAD +  alleviated neuroinflammation, attenuated central nervous system (CNS) demyelination, and improved the disease score of EAE mice. NAD +  promoted expression of the cytokine interleukin 17A (IL-17A).",
author="Zheng, Bin
and Ma, Jianhua
and Deng, Xiao
and Pan, Jiangang
and Liao, Feng",
pages="345--354",
doi="10.5114/fn.2025.147649",
url="http://dx.doi.org/10.5114/fn.2025.147649"
}